MARKET

OYST

OYST

OYSTER POINT PHARMA, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.30
-0.69
-3.29%
After Hours: 20.30 0 0.00% 16:00 09/21 EDT
OPEN
20.57
PREV CLOSE
20.99
HIGH
21.00
LOW
20.12
VOLUME
80.61K
TURNOVER
--
52 WEEK HIGH
41.37
52 WEEK LOW
13.26
MARKET CAP
522.78M
P/E (TTM)
-7.0157
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company
GlobeNewswire · 09/11 13:00
Chief Commercial Officer John Snisarenko Just Bought 133% More Shares In Oyster Point Pharma, Inc. (NASDAQ:OYST)
Simply Wall St. · 08/17 15:33
Oyster Point Pharma shares are trading higher after the company reported better-than-expected Q2 EPS results.
Benzinga · 08/05 12:21
Oyster Point Pharma shares are trading higher after the company reported better-than-expected Q2 EPS results.
Benzinga · 08/05 12:21
Oyster Point Pharma Q2 EPS $(0.66) Beats $(0.80) Estimate
Oyster Point Pharma (NASDAQ:OYST) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.80) by 17.5 percent.
Benzinga · 08/05 12:07
Oyster Point Pharma Q2 EPS $(0.66) Beats $(0.80) Estimate
Oyster Point Pharma (NASDAQ:OYST) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.80) by 17.5 percent.
Benzinga · 08/05 12:07
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
* OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020 * Cash and Cash Equivalents of $226.7 million as of June 30, 2020 * Conference Call and Webcast Sch
GlobeNewswire · 08/05 11:00
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020
Conference Call and Webcast Scheduled for August 5, 2020, 8:30 am ETPRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat
GlobeNewswire · 07/31 20:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OYST stock price target is 63.25 with a high estimate of 71.00 and a low estimate of 57.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 18.81M
% Owned: 73.04%
Shares Outstanding: 25.75M
TypeInstitutionsShares
Increased
25
3.63M
New
33
1.13M
Decreased
7
65.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Founder/Director
Michael Ackermann
President/Chief Executive Officer/Director
Jeffrey Nau
Chief Financial Officer/Primary Contact
Daniel Lochner
Other
John Snisarenko
Director
Mark Murray
Independent Director
Ali Behbahani
Independent Director
William Link
Independent Director
Clare Ozawa
Independent Director
Benjamin Tsai
Independent Director
Aimee Weisner
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average OYST stock price target is 63.25 with a high estimate of 71.00 and a low estimate of 57.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OYST
Oyster Point Pharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate is OC-01 (varenicline), a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity, and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oyster Point Pharma Inc stock information, including NASDAQ:OYST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OYST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OYST stock methods without spending real money on the virtual paper trading platform.